This disconnect underscores ongoing questions about prioritisation and access
Kyriazopoulou V, Parparousi O, Vagenakis A
The focus remains on compound identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, and published literature boundaries
However, these uses are still under research, and no conclusive clinical recommendations exist for routine use
Maximum FDA-approved for weight loss (Wegovy): 7.2 mg weekly (as of March, 2026) Maximum FDA-approved for diabetes (Ozempic): 2.0 mg weekly In the U.S., the FDA guidelines currently cap the maximum suggested weekly dosage of semaglutide to 7.2 mg for injections
Why Retatrutide 10mg Stands Out Retatrutides triple-receptor agonism offers a unique advantage over dual-agonist peptides, making it one of the most potent metabolic modulators under clinical investigation